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Dendritic cells (DCs) are the dominant class of antigen-presenting cells in humans and 
are largely responsible for the initiation and guidance of innate and adaptive immune 
responses involved in maintenance of immunological homeostasis. Immature dendritic 
cells (iDCs) phagocytize pathogens and toxic proteins and in endosomal vesicles 
degrade them into small fragments for presentation on major histocompatibility complex 
(MHC) II receptor molecules to naïve cognate T cells (Th0). In addition to their role in 
stimulation of immunity, DCs are involved in the induction and maintenance of immune 
tolerance toward self-antigens. During activation, the iDCs become mature. Maturation 
begins when the DCs cease taking up antigens and begin to migrate from their location 
in peripheral tissues to adjacent lymph nodes or the spleen where during their continued 
maturation the DCs present stored antigens on surface MHCII receptor molecules to 
naive Th0 cells. During antigen presentation, the DCs upregulate the biosynthesis of 
costimulatory receptor molecules CD86, CD80, CD83, and CD40 on their plasma mem-
brane. These activated DC receptor molecules bind cognate CD28 receptors presented 
on the Th0 cell membrane, which triggers DC secretion of IL-12 or IL-10 cytokines 
resulting in T cell differentiation into pro- or anti-inflammatory T cell subsets. Although 
basic concepts involved in the process of iDC activation and guidance of Th0 cell differ-
entiation have been previously documented, they are poorly defined. In this review, we 
detail what is known about the process of DC maturation and its role in the induction of 
insulin-dependent diabetes mellitus autoimmunity.
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iNTRODUCTiON
Insulin-dependent diabetes mellitus (IDDM), also referred to as type 1 diabetes, is a metabolic 
disease that prevents blood sugar from entering the cells of the body. Onset of IDDM has been 
identified in children as early as 3–5 years of age. Disease onset results from dysregulated immune 
cell elimination of the pancreatic islet β-cells the source of insulin production (1, 2). Currently, 
treatment for IDDM remains palliative based on multiple injections daily of insulin to maintain 
normal blood sugar levels. The increasing prevalence of IDDM, its progressive complications, and 
the lack of effective preventive and curative strategies require a greater effort to develop effective 
and safe methods for persistent restoration of normal blood sugar levels in IDDM patients. So 
far, no safe and effective treatment is available to control the onset and progression this life-long 
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debilitating disease (3). The loss of β-cell function in IDDM is 
mediated principally by CD4+ and CD8+ T cells, and autoreactive 
effector CD8+ T cells (CTLs) were shown to be responsible for 
islet β-cell destruction in the non-obese diabetic (NOD) mouse 
and in human IDDM (4–6).
Autoreactive effector thymic (T) cells were shown to trans-
fer IDDM to immune-compromised hosts (4). Based on its 
wide spread nature and specific autoantigens shown to cause 
diabetes onset, IDDM became established as a prototypical 
autoimmune disease. High blood glucose levels are induced 
in IDDM when dendritic cells (DCs) interact with potential 
autoreactive effector Th0 cells in peripheral tissues. The DCs 
were shown to guide differentiation of autoreactive T cells into 
pro-inflammatory effector cells capable of halting islet insulin 
biosynthesis by inducing β-cell death (1, 5–12). However, lit-
tle is known concerning the kinetics and phenotypic changes 
that occur in DCs during IDDM development in the NOD 
mouse pancreas. While peri-islet accumulation of conven-
tional myeloid progenitor derived DCs (cDCs) can appear in 
4-week-old NOD mice, lymphoid progenitor derived plasma-
cytoid DCs were shown to surround the islets of Langerhans 
in mice 10 weeks old (9). The gathering of DCs surrounding 
the islets occurred along with an influx of lymphocytes (3, 9). 
Reinforcing the major role for DC participation in diabetes 
development, the removal of DCs in NOD mice resulted 
in reduced CD4+ T  cell activation, stimulation of insulitis, 
the production of antibodies, and the infiltration of pro-
inflammatory Th1/Th17 cells into pancreatic tissues (3, 13). 
The authors showed that transfer of myeloid DCs (mDCs) into 
mice without DCs induced IDDM onset. The experimental 
findings reinforce the importance of DC stimulation of IDDM 
autoimmunity.
Dendritic cell activation is required for assessment of tolero-
genesis. An important feature of tolerogenic DCs is their ability 
to secrete TGF-β as well as the anti-inflammatory cytokine IL-10 
both of which inhibit T lymphocyte secretion of IL-2 and IFN-γ 
inflammatory cytokines (14–17). During the immunological 
steady state also referred to as immunological homeostasis, DCs 
were shown to secrete high levels of IL-10 that modulates acti-
vation of neighboring myeloid DCs and promotes the de novo 
induction of tolerogenic DCs. In view of their pivotal role in 
regulating T cell immunity, DCs may alter the balance between 
pro-inflammatory T  cells and regulatory T  cells (Tregs) in 
IDDM. Studies of mouse IDDM showed that mDCs can possess 
a hyper-inflammatory phenotype (18). In 1973, Steinman and 
his colleagues first identified DCs and their ability to stimulate 
T  lymphocytes, which ultimately lead to the realization that 
DCs were key regulators of both protective immune responses 
and tolerance to self-antigens (6, 19–21). These experiments 
demonstrated DC existence in two different states identifiable 
by morphological, phenotypic, and functional markers and 
became the first description of DC maturation. With the pro-
gress of time, increasing numbers of DC subsets continued to 
emerge, demonstrating the ability of DCs to differentiate into 
a variety of specialized antigen-presenting cells (APCs) capable 
of establishment of immunological tolerance under a variety of 
tissue conditions.
iMMUNe CeLL-iNDUCeD iDDM
Insulin-dependent diabetes mellitus is caused by dysregulated 
immune cell destruction of the insulin-generating pancreatic 
islet β-cells. Assault on the β-cells begins with invasion of the 
islets by mononuclear cells in an acute inflammatory reaction 
termed “insulitis,” that leads to a progressive destruction of 
the majority of insulin producing β-cells during disease onset 
that develops silently over a period of several to many years 
(8, 22). Clinical symptoms of diabetes generally do not appear 
until more than 70% of the beta-cell population has been 
destroyed (22). Apoptosis appears to be the general mecha-
nism by which β-cell death occurs in both rodent IDDM 
models and in human islets isolated from IDDM patients 
(22, 23). While the mechanism of β-cell destruction in IDDM 
remains unclear, it was shown to involve several steps: (1) 
expression of the TNF type-II transmembrane protein fam-
ily member Fas ligand on activated CD8+ cytotoxic T  cells 
and the Fas receptor present on the β-cell membrane; (2) the 
release of the cytolytic protein perforin and the proteolytic 
enzymes granzyme by CD8+ T  cells; (3) pro-inflammatory 
cytokine secretion IL-β, TNF-α, and IFN-γ by islet infiltrat-
ing T  cells; (4) synthesis of reactive oxygen intermediates 
(ROS) that include nitric oxide secreted by DCs, β-cells, 
and macrophages; and (5) the activation of immature DCs 
(22–24). The death of β-cells during insulitis progression 
is likely triggered by autoantigen-activated DC stimulation 
of naive autoreactive Th0 cell differentiation into effector 
T cells that produce a variety of pro-inflammatory cytokines 
and free radical molecules (23). Additional immune cell 
types that facilitate IDDM onset include antibody produc-
ing B-cells and scavenging macrophages. Autoantibodies are 
generated by B-cells against early islet autoantigens such as 
proinsulin and glutamic acid decarboxylase 65, which are the 
first indicators of β-cell autoimmunity. NOD mice deficient 
in B cell production due to the presence of Igμ mutations do 
not develop IDDM (25, 26). In addition, skewing the B cell 
autoantibody repertoire toward islet antigens, for example, 
through transgenic expression of insulin-binding immu-
noglobulin heavy chains in B  cells also promoted diabetes 
development (27).
Despite evidence for the involvement of B  cells in IDDM 
development, their exact functions remain unclear. Autoantibody 
secretion or antigen presentation to T cells by MHCII receptors 
has been described as the two most identified functions of B cells 
(28). These experiments indicate that IDDM is not induced by 
antibodies or B cells only (28). B cells were shown by Silva et al. to 
enhance islet autoreactive CD4+ T cell promotion of IDDM onset 
(28). Additional studies have shown that both natural killer cells 
and macrophages directed to the pancreatic islets by CD4+ T cell 
can also stimulate β-cell death (29).
The primary function of DCs in IDDM is antigen presenta-
tion outside and within the islet (13, 30). These studies show 
that autoantigen presentation is essential for the initiation and 
continued development of IDDM. Analysis of NOD mouse bone 
marrow-derived DCs suggests that they synthesize increased 
levels of IL-12 subunit and NF-κB expression (31, 32).
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DC ACTivATiON: TRANSLATiON FROM 
iNNATe iNTO ADAPTive iMMUNiTY
Autoimmune disease attack in IDDM resides largely in the 
progression of DCs from an immature to a mature (active) state. 
Two distinct mechanisms underlie innate DC activation, both of 
which result in development of a pro-inflammatory state (33). 
Distinctions occur in the recognition mechanism for molecules 
conserved among pathogens. The first mechanism is centered on 
portions of pathogens recognized by receptors on the surface of 
DCs commonly referred to as “pathogen-associated molecular 
patterns” (PAMPs), while the second mechanism involves PAMP-
independent DC activation that occurs in DC interactions with 
self-molecules (autoantigens) or alterations in the cell’s internal 
composition.
DC Maturation (Activation)
Dendritic cells are involved in the development of both innate 
and adaptive arms of the human immune system (34). Immature 
DCs located in the periphery screen foreign antigens including 
viruses and microbial pathogens. During uptake and processing 
of foreign antigens, immature DCs begin to mature and migrate 
to the spleen or adjacent lymph nodes. During maturation, the 
DCs begin to synthesize peptides that include major histocom-
patibility complex (MHC) II molecules, CD40, CD80, and CD86 
costimulatory molecules and proteins like CD83 and DC-LAMP 
that have little known functions (35). Upon maturation, DCs 
stimulate naïve T  cells to differentiate into T-cells capable of 
generating anti- or pro-inflammatory immune responses (34, 36, 
37). Further, DCs in the periphery were shown to induce immune 
tolerance in communication with the spleen or in the periphery 
(19, 21). Thus, DCs can be involved in the regulation of a wide 
variety of immune responses. DCs located in the periphery can 
differentiate from a state of immaturity residing and capturing 
passing antigens, to a state of maturity where they become mobile 
APCs capable of priming naïve T cells. DCs are able to identify 
and convert antigens into immunogens and express antigen-
presenting receptor molecules that include MHCI, MHCII 
receptors, cytokines, chemokines, costimulatory molecules, and 
proteases that work in concert to stimulate specific immune 
responses from naïve T  cells. The induction of DC-mediated 
T cell immune responses may vary from Th2 lymphocytes that 
induce immunological tolerance to the differentiation of Th1 and 
Th17 lymphocytes responsible for pro-inflammatory immune 
responses to pathogens or toxins. Variability in DC-mediated 
immune responses may depend on myeloid DC1s or lymphoid 
DC2s and the stage of maturation stimulated by signals from 
the microenvironment (38, 39). The capacity of DCs to regulate 
immune responses is directly related to their state of activa-
tion. Following antigen processing, environmental factors may 
stimulate DCs to become mature. These factors may include 
bacterial-structural or soluble antigens [e.g., lipopolysaccharide 
(LPS)], inflammatory cytokines, binding to cell surface receptors 
that include CD40 and members of the TNFR family as well 
as viral dsRNA. During the development of maturity, DCs go 
through phenotypic and functional alterations. MHC molecules 
are moved from endocytic compartments to the surface of the 
DC during maturation. The uptake of antigens is downregulated, 
and there is an increase in costimulatory molecules expressed on 
the cell surface. Further, morphological changes in the DC during 
maturation include cytoskeleton reorganization, the formation 
of dendrites, as well as the secretion of proteases, cytokines, and 
chemokines. During migration from the periphery to the spleen 
and lymph nodes, the DCs express specific adhesion molecules 
and chemokine receptors on their cell surface (39).
PAMP-Dependent DC Activation
During DC maturation, individual DC subsets may perform 
specialized functions that include changes in migratory patterns, 
cytokine profiles, kinds of antigens processed, localization in 
specific tissues, and their presence or absence during the develop-
ment of inflammation or during immunological homeostasis (3, 
19, 21). A function shared by all subsets of DCs is the kind of 
immune-stimulatory or immune-suppressive signals delivered 
to cells of the vertebrate immune system that result in the devel-
opment of immune responses. Two major steps are involved in 
the development of the described functions. The first step is a 
requirement for antigen identification. Step 2 involves MHCII 
antigen presentation accompanied by appropriate secondary sig-
nals provided by the DC that stimulate effector T cell activation. 
It is well known that DCs identify antigens that bind receptors 
on their cell membrane. Pathogen-specific molecular signals that 
stimulate a DC response are referred to as PAMPs. If the damaging 
stimulus comes from molecules in the cell environment, they are 
referred to as damage-associated molecular patterns (DAMPs). 
These molecular patterns are composed of molecules common 
to pathogens or the environment that are not present in the host. 
The PAMPs provide an external signal to immature DC recep-
tors that initiate a pro-inflammatory response to the infectious 
pathogen or toxin. The release of uric acid, DNA, or ATP from a 
cell can be an alert sign to DCs for sensing the presence of cells 
under stress from microbial invasion or cancer caused necrotic 
cell death (3, 40). Detection of both DAMPs as well as PAMPs 
occurs via DC surface and internal receptors commonly referred 
to as pattern recognition receptors (PRRs). These receptors can 
detect end products of glycation (RAGE), or helicases such as 
the RIG-I-like receptors (RLRs) are capable of recognizing viral 
replication in the cell, or NOD-like receptors (NLRs), responsible 
for intracellular recognition of PAMPs. Finally, toll-like receptors 
(TLRs) on the surface or internal within the DC are capable of 
recognizing exogenous and endogenous pathogenic bacterial and 
viral products.
Viral envelope proteins and ssDNA from the virus genome, the 
LPS and flagellin proteins from bacteria, zymosan from fungus, 
and profilin from the parasitic protozoan Toxoplasma gondii 
are typical PAMPs recognized by TLRs on the DC. In contrast, 
“danger” signals derived from cells or from the environment. 
For example, the release of molecules such ATP, DNA, or uric acid 
from a cell can be a warning sign to DCs for sensing the presence 
of cells under stress from microbial invasion, or cancer caused 
necrotic cell death and are characteristic DAMPs (3, 40). Several 
DAMPs such as heat shock and S100 proteins are recognized by 
RAGE. Other DAMPs, such as ATP and uric acid activate NLRs 
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and induce the formation of inflammasomes that may trigger 
downstream secretion of pro-inflammatory cytokines such as 
IL-1β and IL-18. All immunogenic oligonucleotides bind RLRs, 
which require recognition to induce a signaling response within 
the DC. The TLRs are the most common of the PRRs. In addition 
to recognizing a variety of PAMPs and DAMPs, they have been 
implicated in the initiation of autoimmune diseases. Those TLRs 
embedded in the DC membrane that include TLR4, TLR5, and 
TLR1/2, and TLR2/6 heterodimers recognize bacterial membrane 
components The TLRs 3, 7, 8, and 9 that recognize viral immuno-
genic oligonucleotides are internal to the DC and are embedded in 
the endosomal membrane (3, 40). High levels of TLR2 and TLR4 
expression on myeloid DCs and TLRs TLR7 and TLR9 present 
in pDCs may have specific functions in autoimmune disease in 
which molecular mimicry or autoantibodies to essential nucleic 
acids are a potential underlying mechanism for autoimmune 
disease onset.
PAMP-independent DC Activation
In 1994, Matzinger proposed an alternative mechanism for DC 
activation that suggested activation of DCs occurs in response 
to recognition of host-generated molecules released by cells 
undergoing the process of necrosis (41). The host endogenous 
danger signals were considered to mimic PAMPs acting as ligands 
for PRRs, a concept additionally supported by suspected TLR 
involvement in mouse skin graft rejection (40, 42, 43). However, 
because a number of TLRs signal in response to virus infection, 
a study was carried out to determine whether virus-triggered 
TLR signaling was required for myeloid DC maturation and 
induction of antiviral immunity. This study showed that mouse 
myeloid DCs mature normally after infection in vivo or in vitro 
with Sendai virus (SeV) in the absence of TLR3, 7, 8, or 9 signal-
ing (44). The demonstration that DC maturation by SeV requires 
virus replication in the absence of a TLR response provides evi-
dence for the existence of Matzinger’s intracellular pathway and 
demonstrates its critical role in DC-mediated antiviral immunity. 
Elucidation of this pathway establishes a basis for further study 
into the diversity of mechanisms responsible for virus-induced 
DC maturation and immunity.
THe iMPACT OF DC COSTiMULATiON ON 
THe iNDUCTiON OF iDDM
Many studies have shown that antigen delivery to DCs upregu-
lates expression of the DC costimulatory molecules B7-1 (CD80) 
and B7-2 (CD86) known to induce T  cell receptor signaling 
and promote T  cell activation. Synthesis of the glycoprotein 
DC-LAMP, expressed in the DC lysosomal MHC II compart-
ment, is stimulated following the binding of CD154 to the CD40 
receptor (CD40R) found on the surface of DCs. This glycoprotein 
was suggested to function in promoting antigen processing and 
transport of antigen-loaded MHC II complexes to the cell surface 
for presentation to T  cells (35). Members of the B7 family are 
structurally related cell-surface proteins that regulate immune 
responses by delivering costimulatory or co-inhibitory signals. To 
date, eight family members have been identified that include the 
most recognized DC activating costimulatory molecules CD80 
(B7-1) and CD86 (B7-2), as well as CD274 [the programmed cell 
death-1 ligand (PD-L1)], CD273 [the programmed cell death-2 
ligand (PD-L2)], CD275 (an inducible costimulatory ligand), 
CD276 (B7-H3), B7-H4, and B7-H6 (45). Members of the B7 
ligands are expressed on lymphoid and other tissues (45). The 
importance of B7 family signaling in the regulation of immune 
responses is clear from their demonstrated role in the develop-
ment of immunodeficiency and autoimmune diseases (45). 
The diverse signals delivered by B7 ligands emphasize the great 
potential for treatment of cancer, including leukemia’s and for the 
treatment of tissue-specific autoimmune diseases like IDDM.
How Costimulatory Molecules Mediate 
inflammation
PD-L1 and PD-L2
The PD-L1 and PD-L2 may be found on the surface of immature 
dendritic cell (iDC), and on mature dendritic cells as well as IFN-γ-
treated monocytes and are involved in directing programmed cell 
death-1 (PD-1), via receptor family members CD28 and CTLA4 
expressed on the surface of activated T cells (46, 47). Programmed 
cell death ligand PD-1 contains a tyrosine-linked inhibitory motif. 
Mice shown to be deficient in PD-1 are susceptible to the devel-
opment of autoimmune disorders suggesting the existence of a 
defect in the mechanism of tolerance. Monoclonal Ab blockade 
of PD-L2 on DCs was shown to enhance T cell proliferation and 
the production of IFN-γ and IL-10. Blockade of PD-L1 resulted 
in a more modest form of autoimmunity (36). Inhibition of both 
PD-L1 and PD-L2 stimulated an additive effect. Monoclonal 
antibody and Fab-enhanced T cell activation studies showed that 
both PD-L1 and PD-L2 can inhibit T cell activation (47, 48). The 
activation of T cells was most enhanced using weak APCs such 
as iDCs and IL-10-pretreated mDCs, and least activated using 
strong APCs such as mDCs (46). The experimental findings 
suggest iDCs contain a balance of stimulatory vs inhibitory mol-
ecules that favors inhibition of DC activation, and indicate that 
PD-L1 and PD-L2 function to reduce the immunostimulatory 
capacity of iDCs. This result suggests the propensity for an IDDM 
inflammatory response in DCs may be due to the lack of PD-L1 
and/or PD-L2 expression. Both Tregs and the PD-1: PD-ligand 
(PD-L) pathways are involved in termination of the immune 
responses (49). Thus, their elimination may result in a loss of 
immunological tolerance and lead to autoimmunity. The PD-1: 
PD-L pathway was shown to block the function of self-reactive 
T  cells and protect against autoimmunity in several ways (50). 
PD-L1 is constitutively expressed by most hematopoietic cells and 
can be further upregulated upon activation. In contrast, PD-L2 
is inducible on DCs, macrophages, and B cells. Both PD-L1 and 
PD-L2 are ligands of PD-1, which is expressed on activated B cells 
and T-cells as well as resting T-cells (49, 50).
Costimulatory Factors CD86, CD83, CD80, and CD40
The DC surface receptor costimulatory molecules CD86, CD80, 
CD83, and CD40 generate important signals for stimulating naive 
T cell differentiation and may inhibit oral tolerance in not only 
IDDM but also inflammatory bowel disease (IBD) and multiple 
sclerosis (5, 6, 51, 52).
FiGURe 1 | Suggested signaling pathways for induction of the immunosuppressive catabolic enzyme indoleamine 2,3-dioxygenase (iDO1) in 
vertebrate dendritic cells (DCs). Immunosuppressive cytokine TGF-β and CD40 ligand stimulate tolerogenic DC development by inducing IDO1 synthesis via 
activation of the non-canonical NF-kB signaling pathway as described by Kim et al. (73). Vaccine stimulation of TGF-β may also be involved in the induction of IDO1 
biosynthesis through induction of transcriptional activator molecules SMAD2 and 3 phosphorylation ultimately leading to IDO1 biosynthesis. Stimulation of CD40 
receptor (TNF-receptor family), by CD40 ligand phosphorylates TRAF2, 3, and 6 proteins stimulating NF-kB non-canonical pathway upregulation of IDO1 
biosynthesis directly or through phosphorylation of SMAD2 and 3. Bacterial lipopolysaccharide (LPS) binding to TLR4 initially stimulates IDO upregulation but 
ultimately triggers DC maturation through upregulation of costimulatory factors CD80/CD86.
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The DC costimulatory factor CD86 is synthesized and pre-
sented on DCs and other APCs that upon T cell recognition of 
an antigen presented on MHCII, which provides costimulatory 
signals necessary for T  cell activation and survival by acting 
as a ligand for two receptor proteins on the T cell surface. The 
CD86 costimulatory factor can bind to either CD28 presented on 
the T cell (for autoregulation and intercellular association) and 
to CTLA4 synthesized by the T cell (to attenuate immune sup-
pression and cellular disassociation). Pancreatic islet endothelial 
cells (ECs) were shown to form a barrier to autoreactive T cell 
transmigration during the development of islet inflammation 
in the development of IDDM (53, 54). In a study conducted 
by Lozanoska-Ochser et  al., the goal was to determine the 
significance of costimulatory molecule synthesis by islet ECs. 
The authors showed that human islet ECs constitutively express 
both the ICOS ligand and CD86 (B7-2) but do not constitutively 
express the costimulatory molecules CD40 or CD80 (B7-1) (55). 
Examination of the functional activity of islet EC-expressed 
CD86 was accomplished by coculture of resting islet ECs with 
CD4 T cells stimulated by ligation with just CD3. Proliferation 
of T cells in the coculture was blocked by monoclonal antibodies 
against CD86, demonstrating that costimulatory factor effects are 
provided to ECs by the expression of CD86 (55, 56). Together, the 
above data implicate a new function for CD86 on islet ECs and on 
the vasculature, an essential function for promoting adhesion and 
expansion of newly activated T cell populations.
The costimulatory protein CD83 was at first shown to be a 
marker for the maturation of DCs (57). However, further evi-
dence suggests that CD83 may also be involved in the regulation 
of B cell function, thymic T cell maturation, and peripheral T cell 
activation (58–60). The expression of CD83 mRNA is differen-
tially regulated in native CD4+CD25+ regulatory T cells (nTregs). 
The activation of nTregs was shown to rapidly synthesize large 
amounts of CD83 (58, 60). These experimental findings show that 
Treg CD83 expression may be involved in the in vivo develop-
ment of regulatory CD4+ T cells.
A member of the tumor necrosis factor receptor superfamily, 
costimulatory factor CD40R, can be expressed on the surface of 
many cell types including DCs, macrophages, B cells, microglia, 
ECs, epithelial cells, and keratinocytes (61–63). The CD154 ligand 
for CD40R is briefly synthesized on the membrane of activated 
CD4+ T cells and is also synthesized on immune cells involved 
in the development of autoimmunity (64, 65). Interactions 
between CD40R and its ligand CD154 results in movement of 
FiGURe 2 | Dendritic cell (DC) and T cell subsets in vertebrates. Following the addition of GMCSF and IL-4, monocytes undergo differentiation into immature 
dendritic cells (iDCs). The addition of various cytokines (adjacent to arrows) permits iDC differentiation into three different DC subsets that include mature dendritic 
cells, semi-mature dendritic cells, and regulatory dendritic cells (rDCs). Only rDCs and semi-mature dendritic cells express costimulatory factors CD86 and CD80 
and secrete the cytokine IL-10 known to stimulate naïve Th0 cell differentiation into Th2 cells and Th3 or Tr1 regulatory T cells. In contrast, mDCs secrete 
pro-inflammatory cytokines IL-6 and IL-12 that stimulate naïve Th0 cell development into pro-inflammatory Th1 and Th17 lymphocytes.
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CD40R into cholesterol-rich membrane microdomains and the 
binding of TNFR-associated factors (TRAFs) to its cytoplasmic 
tail as recently described by Senhaji et  al. (66) and others (61, 
67–71). The CD40R receptor was also shown to directly bind 
TRAF2, TRAF3, TRAF5, and TRAF6 and to indirectly associate 
with TRAF1 (61, 68, 72) (Figure 1). These molecular exchanges 
result in the upregulation of mitogen and stress-activated protein 
kinase (MAPK/SAPK) cascades, the activation of transcription 
factors, the secretion of cytokines, the expansion and morpho-
genesis of B cells into plasma cells that secrete Ig antibodies, and 
the development of humoral memory cells. TRAF molecules are 
associated with overlapping interchangeable and specific CD40-
driven interactions (63, 72). For instance, TRAF6 is essential 
for CD40− activation of JNK and IL-6 synthesis in B cells, while 
TRAF2 is needed to activate NF-kB, while TRAF3 acts as a nega-
tive regulator to inhibit CD40 signaling.
Suppression of DC Activation
Oral administration of autoantigens to NOD mice was shown to 
protect against the development of IDDM (74). More recently, the 
non-toxic B subunit of the cholera enterotoxin (CTB) from Vibrio 
cholerae used as a carrier molecule for linked autoantigens such as 
proinsulin was shown to induce oral tolerance in NOD mice (75). 
Studies in our lab and others have shown that oral delivery of CTB 
conjugated to specific autoantigens greatly enhanced autoantigen 
protection against the development of autoimmunity in animal 
models representing several tissue-specific autoimmune diseases 
(76–78). A C-terminal conjugate of the cholera toxin B subunit 
(CTB) with proinsulin (CTB-INS) was shown to suppress dia-
betes onset and partially ameliorate disease progression in NOD 
mice (79, 80).
The role of CTB in CTB-INS activation of iDCs in regulation 
of IDDM onset was assessed at an early stage of the human pro-
inflammatory immune response (6). In this study, monocyte-
derived immature DCs (moDCs) isolated from umbilical 
cord blood were incubated with CTB-INS. The fusion protein 
specifically increased plasma membrane expression of DC toll-
like receptor 2 (TLR2). Inoculation of immature moDCs with 
CTB alone stimulated DC costimulatory factors CD86 and 
CD83 synthesis. In contrast, incubation of moDCs with CTB-
INS fusion protein maintained at baseline levels or suppressed 
biosynthesis of both CD86 and CD83 costimulatory factors below 
unvaccinated moDC levels. Incubation of monocyte-derived 
DCs with increasing amounts of insulin stimulated DC matu-
ration by increasing the biosynthesis of both CD86 and CD83 
costimulatory factors. Treatment of moDCs with CTB-INS fusion 
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protein inhibited synthesis of the pro-inflammatory cytokine 
IL-12/23 p40 subunit protein while increasing secretion of the 
immunosuppressive cytokine IL-10 suggesting that fusion of 
CTB to insulin may be required for naïve Th0 cell differentiation 
into immunosuppressive Th2 or Tregs. The data suggest TLR2 
may be involved in CTB-INS inhibition of DC-induced IDDM 
onset. Further, linking CTB to a “self ” protein was required for 
DC stimulation of immune tolerance as co-delivery of CTB, and 
insulin did not effectively block the biosynthesis of DC costimu-
latory factors. These findings support the idea that regulation of 
pancreatic β-cell insulitis depends on both CTB activation of DC 
TLR2 receptors and processing of CTB linked to the proinsulin 
autoantigen within the DC.
Disappearance of the monocyte CD14+ marker following 
treatment with the CTB-INS protein suggests the vaccine does 
not interfere with differentiation of monocytes into immature 
DCs (81). Further, DC expression of HLA-DR markers remained 
unaffected (81). The observations that CD86 and CD83 are 
synthesized in CTB-INS-treated DCs at much lower levels than 
untreated DCs suggest the vaccine can induce tolerogenesis in 
CTB-INS-treated DCs (81). The prevention of costimulatory fac-
tor CD86 and CD83 biosynthesis in vaccinated DCs was shown to 
occur simultaneously with biosynthesis of the immunosuppres-
sive tryptophan catabolic enzyme indoleamine 2,3-dioxygenase 
(IDO1) suggesting their potential linkage in CTB-INS-induced 
DC tolerance.
Concerning the mechanism of CTB-INS modulation of DC 
activation, recent experiments indicate that CTB-INS stimulates 
TNFR signaling and induction of IDO1 biosynthesis in human 
DCs (73). Inhibition of the TNFR pathway allowed examination 
of CTB-INS-induced IDO1 biosynthesis in vaccinated DCs. In 
this recent study, monocyte-derived DCs were incubated with 
peptides containing amino acid sequences of the TRAF2, 3 and 
TRAF6 binding sites for CD40. The DCs were then stimulated 
with CD40 ligand (CD154), and CTB-INS. The addition of 
CD40-TRAF2, 3 and CD40-TRAF6 blocking peptides inhibited 
upregulation of IDO1 biosynthesis in response to both CD154 
ligand and CTB-INS. The greatest reduction in IDO1 biosynthe-
sis was observed when both TRAF2, 3 and TRAF6 inhibitors were 
combined (73).
Based on available data, Figure  2 represents current infor-
mation on DC maturation and the role DC maturation plays 
in upregulation of the immune response and development of 
immune tolerance as a mechanism for inhibition of IDDM 
autoimmunity.
CONCLUSiON
The experimental results presented in this review support the 
development of combinatorial vaccine strategies for the develop-
ment of safe and effective immune-regulatory therapeutics for 
prevention and treatment of tissue-specific IDDM autoimmun-
ity. With the progression of time and expanded research efforts, 
an increased understanding of immunological and molecular 
mechanisms underlying DC maturation will expand the applica-
tions of DCs for understanding the nature of autoimmunity and 
for construction of a cure for tissue-specific autoimmune disease 
that for so many generations have plagued mankind.
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